Westlake Precision Birth Cohort (WEBIRTH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04060056 |
Recruitment Status :
Recruiting
First Posted : August 16, 2019
Last Update Posted : September 26, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Diabetes, Gestational Pregnancy in Diabetics Intrauterine Hyperglycemia |
Study Type : | Observational |
Estimated Enrollment : | 2000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Westlake Precision Birth Cohort |
Actual Study Start Date : | August 30, 2019 |
Estimated Primary Completion Date : | July 11, 2022 |
Estimated Study Completion Date : | July 11, 2029 |
- Continuous blood glucose change over 2 weeks [ Time Frame: two weeks after enrollment ]Glucose levels are assessed by continuous glucose monitoring over 2 week
- Adverse birth outcomes [ Time Frame: 9-12 weeks after enrollment ]Risk of preterm birth, low birth weight and small-for-gestational age
- Body composition after delivery [ Time Frame: 6 months and 3 years after delivery ]Body composition (fat mass, lean mass in kg ) are assessed by DXA for both mothers and infants
- Weight changes during early childhood [ Time Frame: at delivery, age of 6 months, 1 year, 3 years and 6 years ]Weight in kilograms
- type 2 diabetes [ Time Frame: 6 years and 10 years after delivery ]Risk of developing type 2 diabetes after the delivery of their children among these women with pregnancy hyperglycemia
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Women aged 18 yrs or older
- Women with GDM or DIP at 24-28 weeks of gestation
- Women intended to deliver at Hangzhou Women's Hospital
- Women intended to remain in Hangzhou with their child for ≥4 years
Exclusion Criteria:
● Women with cancer and other serious medical disorders

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04060056
Contact: Ju-Sheng Zheng, PhD | 86-0571-86915303 | zhengjusheng@westlake.edu.cn |
China, Zhejiang | |
Hangzhou Women's Hospital | Recruiting |
Hangzhou, Zhejiang, China, 310008 | |
Contact: Ju-Sheng Zheng, PhD 86-0571-86915303 zhengjusheng@westlake.edu.cn | |
Contact: Zelei Miao 86-0571-86915303 miaozelei@westlake.edu.cn |
Principal Investigator: | Ju-Sheng Zheng, PhD | Westlake University |
Responsible Party: | Westlake University |
ClinicalTrials.gov Identifier: | NCT04060056 |
Other Study ID Numbers: |
20190701ZJS0007 |
First Posted: | August 16, 2019 Key Record Dates |
Last Update Posted: | September 26, 2019 |
Last Verified: | August 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Precision Nutrition Host and Microbiome Birth Outcomes |
Diabetes, Gestational Pregnancy in Diabetics Hyperglycemia Glucose Metabolism Disorders |
Metabolic Diseases Pregnancy Complications Diabetes Mellitus Endocrine System Diseases |